Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement

BACKGROUND: Leptomeningeal inflammation is associated with increased cortical damage and worse clinical outcomes in MS. It may be detected on contrast-enhanced T2-FLAIR imaging as focal leptomeningeal contrast-enhancement (LME). OBJECTIVE: To assess the safety of intrathecal (IT) rituximab in progre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mult Scler Relat Disord
Hlavní autoři: Bhargava, Pavan, Wicken, Cassie, Smith, Matthew D, Strowd, Roy E., Cortese, Irene, Reich, Daniel S, Calabresi, Peter A, Mowry, Ellen M
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325522/
https://ncbi.nlm.nih.gov/pubmed/30771580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2019.02.013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky